3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
91
Carcinoma, Non-Small-Cell Lung
53
Lung Neoplasms
22
Hodgkin Disease
15
Recurrence
11
Lymphoma
10
Neoplasm Metastasis
9
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasms
6
Sarcoma
4
Rhabdomyosarcoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Adenocarcinoma of Lung
4
Multiple Myeloma
3
Mesothelioma, Malignant
3
Mesothelioma
3
Breast Neoplasms, Male
3
Uterine Cervical Neoplasms
2
Ovarian Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lymphoma, Large-Cell, Anaplastic
2
HER2-negative Breast Cancer
2
Fallopian Tube Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Brain Neoplasms
2
Advanced Breast Cancer
2
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metatropic dwarfism
×
Vinorelbine
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts